FD
FDMT.O
—
NASDAQ
Biotechnology
4D Molecular Therapeutics Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-187,2 %
ROE
-27,7 %
Net margin
-164,4 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$10,38
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
4D Molecular Therapeutics Inc is a biotechnology company that generates revenue through the development of molecular therapeutics, operating within the Health Care sector.
Business. 4D Molecular Therapeutics Inc is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange under the ticker symbol FDMT.O. Specific details regarding operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
JANUS HENDERSON GROUP PLC
largest disclosed fund holder
Profitability→
-27,7 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to FDMT.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
4D Molecular Therapeutics Inc is a biotechnology company operating within the Health Care sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange under the ticker symbol FDMT.O. Specific details regarding operating segments and geographic revenue mix are not available.
Classification85 %
SectorHealth Care
Industry groupBiotechnology
AI synthesis
GENERATED(a) Capital structure and liquidity: The company maintains a debt-free balance sheet with a debt-to-equity ratio of 0.0. Total assets stand at $566.7 million, while total liabilities are $61.0 million, resulting in total equity of $505.7 million. Cash and equivalents are reported at $60.2 million. Despite the strong equity position, operating cash flow is negative at -$109.1 million, indicating a reliance on existing cash reserves or potential future financing to fund operations. The current ratio is not explicitly provided, but the low liability base relative to equity suggests a conservative capital structure.
(b) Profitability and returns: The company is not yet profitable, reporting a net income of -$140.1 million and an operating income of -$159.5 million. Return on equity is -27.71%, and return on assets is -24.72%, reflecting the significant investment phase typical of early-stage biotechnology firms. These negative returns are consistent with the industry norm for companies in the clinical development phase, where R&D expenses outweigh revenue generation.
Key takeaways
- The company is debt-free with a strong equity base of $505.7 million.
- Negative profitability with a net loss of -$140.1 million and negative operating cash flow of -$109.1 million.
- Revenue of $85.2 million suggests some commercial activity, but customer concentration risk is present.
- Low liquidity and dilution risks indicate a stable capital structure for the near term.
- No significant recent events or filings have been detected.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$10,09
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$505.7M
Net cashⓘ
$60.2M
Current ratioⓘ
—
Debt / equityⓘ
—
ROAⓘ
-24.7%
ROEⓘ
-27.7%
Cash conversionⓘ
78.0%
CapEx / revenueⓘ
0.6%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
— missing data
Supply chain
— missing data
Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution11 analysts
Strong buy3
Buy6
Hold2
Sell0
Strong sell0
12-month price target$28,22 · Median $29,00
Low $17,00High $36,00
Operating income · consensus-300,0M USD
EPS surprise
+38,4 %
reported vs consensus · beat
Revenue surprise
+554,7 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$17,00
Mean$28,22
Median$29,00
High$36,00
Spot$10,09
+179.7 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Op Margin-187,2 %Below median
Net Margin-164,4 %Below median
ROE-27,7 %Above median
Capex / Rev0,6 %Above median
D/E0,00Above median
Cash Conv0,78Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 2 052 130 sh12 exercises · 12 grants12 insiders
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 814 @ $4,14exercise · 2026-06-30
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 5 752 @ $6,49exercise · 2026-06-30
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 9 810 @ $4,14exercise · 2026-06-23
- Director · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $9,42grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $9,42grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $9,42grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $9,42grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $9,42grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $9,42grant · 2026-06-17
- Director · Stock Option (Right to Buy) → Common StockAcquired 50 000 @ $9,42grant · 2026-06-17
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockAcquired 217 000 @ $9,88grant · 2026-03-25
- See Remarks · Stock Option (Right to Buy) → Common StockAcquired 219 000 @ $9,88grant · 2026-03-25
- Director, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 750 000 @ $9,88grant · 2026-03-25
- VP, Finance and Controller · Restricted Stock Units → Common StockDisposed 865exercise · 2026-03-20
- VP, Finance and Controller · Restricted Stock Units → Common StockDisposed 221exercise · 2026-03-20
- Director · Stock Option (Right to Buy) → Common StockAcquired 45 000 @ $7,30grant · 2026-01-05
- VP, Finance and Controller · Restricted Stock Units → Common StockDisposed 220exercise · 2025-12-20
- VP, Finance and Controller · Restricted Stock Units → Common StockDisposed 866exercise · 2025-12-20
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 1 635 @ $4,14exercise · 2025-12-16
- Director · Stock Option (Right to Buy) → Common StockDisposed 9 333 @ $1,14exercise · 2025-12-12
- Chief Financial Officer · Stock Option (Right to Buy) → Common StockAcquired 480 000 @ $10,51grant · 2025-12-09
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 1 635 @ $4,14exercise · 2025-11-17
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 1 084 @ $6,49exercise · 2025-10-24
- Chief Legal Officer · Stock Option (Right to Buy) → Common StockDisposed 1 635 @ $4,14exercise · 2025-10-16
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Equitynet_income / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Return On Assetsnet_income / total_assets
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
Source documents
- 4D Molecular Therapeutics, Inc. Market data — financials · 2026-07-26
- reconciler_enqueue (reconciler) on FDMT.O · 2026-07-26
- 4D Molecular Therapeutics Inc HA canonical relationships · 2026-07-26
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,02 %$49M
- Investment Managers · as of 2026-03-310,01 %$39M
- Investment Managers · as of 2024-06-300,00 %$103M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$25M
- Brokerage Firms · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$10M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Funds · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2025-12-310,00 %$23M
- Investment Managers · as of 2026-03-310,00 %$1M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- John F. MilliganExecutive Chairman of the Board
Insider activity
Net selling0 buys · 15 sellsnet -$2,3M4 insiders · last 365d
- Director, See Remarks · Common StockSold 442 @ $12,84$6K · 2026-07-10
- Director, See Remarks · Common StockSold 15 283 @ $12,01$184K · 2026-07-10
- Director, See Remarks · Common StockSold 42 608 @ $12,87$548K · 2026-07-09
- Chief Legal Officer · Common StockOther 814 @ $4,14$3K · 2026-06-30
- Chief Legal Officer · Common StockSold 6 566 @ $14,00$92K · 2026-06-30
- Chief Legal Officer · Common StockOther 5 752 @ $6,49$37K · 2026-06-30
- Chief Legal Officer · Common StockOther 9 810 @ $4,14$41K · 2026-06-23
- Chief Legal Officer · Common StockSold 9 810 @ $12,00$118K · 2026-06-23
- Director, See Remarks · Common StockSold 114 746 @ $10,47$1,2M · 2026-06-22
- Director, See Remarks · Common StockSold 1 922 @ $10,02$19K · 2026-06-01
- VP, Finance and Controller · Common StockSold 310 @ $8,61$3K · 2026-03-20
- VP, Finance and Controller · Common StockSold 80 @ $8,61$689 · 2026-03-20
- VP, Finance and Controller · Common StockOther 865 · 2026-03-20
- VP, Finance and Controller · Common StockOther 221 · 2026-03-20
- VP, Finance and Controller · Common StockSold 310 @ $8,68$3K · 2025-12-20
- VP, Finance and Controller · Common StockSold 79 @ $8,68$686 · 2025-12-20
- VP, Finance and Controller · Common StockOther 866 · 2025-12-20
- VP, Finance and Controller · Common StockOther 220 · 2025-12-20
- Chief Legal Officer · Common StockOther 1 635 @ $4,14$7K · 2025-12-16
- Chief Legal Officer · Common StockSold 1 635 @ $10,90$18K · 2025-12-16
- Director · Common StockOther 9 333 @ $1,14$11K · 2025-12-12
- Chief Legal Officer · Common StockSold 1 635 @ $10,59$17K · 2025-11-17
- Chief Legal Officer · Common StockOther 1 635 @ $4,14$7K · 2025-11-17
- Chief Legal Officer · Common StockOther 1 084 @ $6,49$7K · 2025-10-24
- Chief Legal Officer · Common StockSold 2 678 @ $12,00$32K · 2025-10-24
Short positioning
11.4Mshares short-14.6% vs prior
15.51days to cover
71.9%short of daily vol
144.1Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
FDMT.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Evidence & claims
From filings & derived data- Current liabilities (annual): USD 43.98MUnknown
- Operating income (annual): USD -159.55MUnknown
- EPS (basic) (annual): USD-PER-SHARES -2Unknown
- Shareholders' equity (annual): USD 505.66MUnknown
- Cash & equivalents (annual): USD 60.24MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -2Unknown
- Revenue (annual): USD 85.21MUnknown
- Total operating expenses (annual): USD 244.76MUnknown
- Total assets (annual): USD 566.71MUnknown
- Current assets (annual): USD 413.13MUnknown
- Capex (annual): USD 536KUnknown
- Operating cash flow (annual): USD -109.08MUnknown
- Shares outstanding (annual): 57.61MUnknown
- Net income (annual): USD -140.11MUnknown
- Total liabilities (annual): USD 61.05MUnknown
- Shares outstanding (annual): 45.79MUnknown
- Shareholders' equity (annual): USD 510.61MUnknown
- Cash & equivalents (annual): USD 149.34MUnknown
- Total liabilities (annual): USD 49.78MUnknown
- Current assets (annual): USD 434.93MUnknown
- Net income (annual): USD -160.87MUnknown
- Operating income (annual): USD -187.84MUnknown
- Total operating expenses (annual): USD 187.88MUnknown
- EPS (basic) (annual): USD-PER-SHARES -3Unknown
Showing 24 of 30 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-07-10INSIDERKirn David sold 442 sh — Director, See Remarks ~$6k
2026-07-10INSIDERKirn David sold 15.3k sh — Director, See Remarks ~$184k
2026-07-09INSIDERKirn David sold 42.6k sh — Director, See Remarks ~$548k
2026-06-30INSIDERBizily Scott sold 6.6k sh — Chief Legal Officer ~$92k
2026-06-30INSIDERBizily Scott transacted 5.8k sh — Chief Legal Officer ~$37k
2026-06-30INSIDERBizily Scott transacted 814 sh — Chief Legal Officer ~$3k
2026-06-30INSIDERBizily Scott disposed of 814 sh Stock Option (Right to Buy) — Chief Legal Officer
2026-06-30INSIDERBizily Scott disposed of 5.8k sh Stock Option (Right to Buy) — Chief Legal Officer
2026-06-23 00:00 UTCINSIDER12 insider transactions — 2026-06 · net sell $1.3M 8 derivative
2026-06-23 00:00 UTCINSIDER12 insider transactions — 2026-06 · net sell $1.3M 8 derivative
2026-06-23INSIDERBizily Scott transacted 9.8k sh — Chief Legal Officer ~$41k
2026-06-23INSIDERBizily Scott sold 9.8k sh — Chief Legal Officer ~$118k
2026-06-23INSIDERBizily Scott disposed of 9.8k sh Stock Option (Right to Buy) — Chief Legal Officer
2026-06-22INSIDERKirn David sold 114.7k sh — Director, See Remarks ~$1.20M
2026-06-17INSIDERTomasello Shawn acquired 50.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERMiller-Rich Nancy acquired 50.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERTHEUER CHARLES acquired 50.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERChacko Jacob acquired 50.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERSBLENDORIO GLENN acquired 50.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERMILLIGAN JOHN F acquired 75.0k sh Stock Option (Right to Buy) — Director
2026-06-17INSIDERGRAY SUSANNAH acquired 50.0k sh Stock Option (Right to Buy) — Director
2026-06-01INSIDERKirn David sold 1.9k sh — Director, See Remarks ~$19k
2026-03-25 00:00 UTCINSIDER9 insider transactions — 2026-03 5 derivative
2026-03-25 00:00 UTCINSIDER9 insider transactions — 2026-03 5 derivative
2026-03-25INSIDERKirn David acquired 750.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer
2026-03-25INSIDERSimms Christopher Paul acquired 219.0k sh Stock Option (Right to Buy) — See Remarks
2026-03-25INSIDERBizily Scott acquired 217.0k sh Stock Option (Right to Buy) — Chief Legal Officer
2026-03-20INSIDERGupta Ashoo transacted 221 sh — VP, Finance and Controller
2026-03-20INSIDERGupta Ashoo transacted 865 sh — VP, Finance and Controller
2026-03-20INSIDERGupta Ashoo sold 310 sh — VP, Finance and Controller ~$3k
2026-03-20INSIDERGupta Ashoo sold 80 sh — VP, Finance and Controller ~$1k
2026-03-20INSIDERGupta Ashoo disposed of 221 sh Restricted Stock Units — VP, Finance and Controller
2026-03-20INSIDERGupta Ashoo disposed of 865 sh Restricted Stock Units — VP, Finance and Controller
Showing the 40 most recent of 61 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage